Alligator Bioscience AB Annual Report 2025

Alligator Bioscience is developing breakthrough immunotherapies for tumor-targeted cancer treatment. The 2025 annual report outlines the company's drug development portfolio, including Mitazalimab, ATOR-4066, and ALG.APV-527, along with strategic collaborations and financial performance.